What is it about?
In this review, we summarized the neurotransmitter alterations in the brain regions involved in cognitive, psychotic and depressive symptoms of Alzheimer's disease. We suggested agonists or antagonists of specific serotonergic receptors to improve these symptoms in Alzheimer's disease. The role of combined GABAA agonists and NMDA antagonists in the prophylaxis and therapy of this disease is discussed.
Featured Image
Why is it important?
This publication not only summarizes the neurotransmitter alterations in the symptoms of Alzheimer's disease, but also describes neural networks in the involved brain areas.
Perspectives
This is a fundamental review with the co-author Rafael Covenas and describes neural networks also in Alzheimer's disease.
Dr Felix-Martin Werner
Euro Akademie Pößneck
Read the Original
This page is a summary of: Serotonergic Drugs: Agonists/Antagonists at Specific Serotonergic Subreceptors for the Treatment of Cognitive, Depressant and Psychotic Symptoms in Alzheimer's Disease, Current Pharmaceutical Design, April 2016, Bentham Science Publishers,
DOI: 10.2174/1381612822666160127113524.
You can read the full text:
Contributors
The following have contributed to this page
